ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Gynecol Oncol · 2026-05-26

Secondary analysis of GOG-0249 (315 of 601 patients with high-intermediate/high-risk early endometrial cancer): 5-year RFS was 58.7% with p53abn (HR 4.0), 74.4% with dMMR and 83.4% with p53wt; molecular group did not predict benefit of VCB/chemotherapy vs pelvic RT.

Secondary analysisn = 315
Kuroki et al. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Vascular surgery · Eur J Vasc Endovasc Surg · 2026-05-18

ESVS focused guideline update for intermittent claudication: paclitaxel coated balloons and stents may be considered only for selected re-stenosis, after discussing uncertain long term safety; SWEDEPAD 2 showed no quality of life or re-intervention benefit at 12 months.

Guideline
Nordanstig et al. Editor's Choice - Focused Update on Paclitaxel Coated Technologies, from the 2024 European Society for Vascular Surgery (ESVS) Guidelines on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent Claudication
Oncology · J Clin Oncol · 2026-05-18

Final 5-year analysis of a phase 2 RCT in 207 patients with HR+/HER2+ early breast cancer: estimated overall survival was 100% with neoadjuvant endocrine therapy plus trastuzumab/pertuzumab vs 97.9% with paclitaxel plus trastuzumab/pertuzumab.

RCTn = 207
Gluz et al. Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Oncology · Eur J Cancer · 2026-05-06

Non-comparative phase II RCT in 141 cisplatin-ineligible patients with R/M HNSCC: 2-year OS was 24.7% with nivolumab plus paclitaxel vs 13.4% with cetuximab, meeting the endpoint, but mortality was higher with nivotax (18% vs 8.3%), mainly respiratory events.

RCTn = 141
Docampo et al. Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.